Exosome Therapy — What It Does, and What Singapore Allows

Exosomes are nano-sized extracellular vesicles that cells use as messengers, carrying growth factors and nucleic acids that influence repair and collagen activity. In aesthetics they are applied topically — most usefully right after a procedure has opened microchannels in the skin.

No — in Singapore exosomes are used topically. Injectable use is a different regulatory category and is not part of practice here. If something is being sold to you as an exosome injection, ask precisely what is in the syringe and under what registration.

The phrase usually refers to a topical exosome application layered over microneedling or laser — using the procedure's microchannels for delivery. It is different from injectable skin boosters such as Rejuran or Profhilo, which are registered injectables.

Used in the post-procedure window, published human studies report faster visible recovery and skin-quality improvements. The evidence base is early — small trials and highly variable products — which is why they are framed here as an adjunct, not a standalone treatment.

Different tools. Rejuran is an injectable polynucleotide with established registration and delivery into the skin; exosomes here are topical signalling adjuncts after procedures. They are complementary rather than competing, and the choice depends on your skin and goals.

Post-fractional recovery support is their clearest use: applied when the channels are open, they are associated with less downtime and smoother recovery. The scar result itself still comes from the resurfacing and subcision plan, not the serum.

Topical scalp exosomes are used as an adjunct within a proper hair protocol — alongside energy-based stimulation and medical therapy. Evidence is early; they are not a standalone cure for androgenetic hair loss.

Commercial products derive exosomes from sources such as stem-cell culture media (human or animal) or plant tissue, then purify and stabilise them. Source, concentration and stability vary widely between brands — one reason product choice is a medical decision.

Applied topically in clinic, reported adverse events in the published literature are low and generally mild. The meaningful safety questions are product quality and honest use — both of which are addressed openly at consultation.

It depends on the underlying procedure plan the exosomes are paired with — recovery support may be single-session; skin-quality programmes are staged. Numbers before assessment would be guesswork.

Over-the-counter “exosome” cosmetics exist, but on intact skin large vesicles largely stay on the surface — the barrier works. The clinical logic depends on procedure-paired delivery, which is not replicable at home.

It depends on the procedure it is paired with and the programme structure. Costs are set out transparently at consultation, before anything is decided.